Literature DB >> 15934315

Expression of survivin, cyclinD1, p21(WAF1), caspase-3 in cervical cancer and its relation with prognosis.

Shi Lu1, Baohua Zhang, Zehua Wang.   

Abstract

The implications of Survivin, CyclinD1, p21(WAF1), Caspase-3 in the development, progression and prognosis in cervical cancer were investigated. By using immunohistochemical SP method, the expression of Survivin, CyclinD1, p21(WAF1), Caspase-3 was detected in 41 cases of cervical cancer, 17 cases of cervical intraepithelial neoplasia (CIN) and 10 cases of normal tissues, and their relation with pathological grade, clinical stage, metastasis and survival time was analyzed. The results showed that the positive expression rate of Survivin, CyclinDl in cervical cancer was significantly higher than in CIN group and normal control group (P < 0.05). The median survival time in the patients with cervical cancer positive for Survivin and CyclinD1 was significantly shorter than in those with negative expression (P < 0.05). The expression of both Survivin and CyclinD1 was not related with tumor grade, clinical stage and metastasis (P > 0.05). The positive expression rate of p21(WAF1) , Caspase-3 in cervical cancer was significantly lower than in CIN group and normal control group (P < 0.05), and had a close relation with tumor grade (P <0.05). The expression of Survivin in cervical cancer in cervical cancer was negatively associated with that of Caspase-3 (P < 0.01), but positively with that of CyclinD1 (P < 0.01). Cox Multivariate analysis revealed that Survivin was the independent prognostic indicator influencing the survival time of the patients with cervical cancer (P < 0.05). It was suggested that the high expression of Survivin or CyclinD1, and low expression of p21(WAF1) or Caspase-3 was closely correlated with the development of cervical cancer. Survivin and CyclinD1 could be used as a useful indicator to predict the prognosis of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934315     DOI: 10.1007/BF02831393

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  15 in total

1.  Cyclin D1 gene expression in human cervical neoplasia.

Authors:  G E Nichols; M E Williams; M J Gaffey; M H Stoler
Journal:  Mod Pathol       Date:  1996-04       Impact factor: 7.842

Review 2.  Cell cycle control and cancer.

Authors:  L H Hartwell; M B Kastan
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

3.  Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus.

Authors:  D S Bae; S B Cho; Y J Kim; J D Whang; S Y Song; C S Park; D S Kim; J H Lee
Journal:  Gynecol Oncol       Date:  2001-06       Impact factor: 5.482

4.  Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.

Authors:  A Suzuki; M Hayashida; T Ito; H Kawano; T Nakano; M Miura; K Akahane; K Shiraki
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

5.  Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix.

Authors:  Han-Seong Kim; Katsuya Shiraki; Sung-Hye Park
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

6.  p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance?

Authors:  O Schwandner; H P Bruch; R Broll
Journal:  Int J Colorectal Dis       Date:  2002-01       Impact factor: 2.571

7.  Activation of cancer-specific gene expression by the survivin promoter.

Authors:  Rudi Bao; Denise C Connolly; Maureen Murphy; Jeffrey Green; Jillian K Weinstein; Debra A Pisarcik; Thomas C Hamilton
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

8.  Apotosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix.

Authors:  Tak-Hong Cheung; Tony Kwok-Hung Chung; Keith Wing-Kit Lo; Mei-Yung Yu; Stan Krajewski; John C Reed; Yick-Fu Wong
Journal:  Gynecol Oncol       Date:  2002-07       Impact factor: 5.482

9.  Cyclin D1 and prognosis in human breast cancer.

Authors:  C Gillett; P Smith; W Gregory; M Richards; R Millis; G Peters; D Barnes
Journal:  Int J Cancer       Date:  1996-04-22       Impact factor: 7.396

10.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Authors:  W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

View more
  8 in total

1.  Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis.

Authors:  Yibing Fan; Juan Chen
Journal:  Bioengineered       Date:  2017-01-04       Impact factor: 3.269

2.  Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential.

Authors:  Matthew W Boudreau; Jessie Peh; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2019-07-16       Impact factor: 5.100

3.  Effects of ursolic acid on the proliferation and apoptosis of human ovarian cancer cells.

Authors:  Xianghong Wang; Liling Li; Bo Wang; Jinyi Xiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

4.  Survivin Overexpression Is Associated with Aggressive Clinicopathological Features in Cervical Carcinoma: A Meta-Analysis.

Authors:  Ke-Yan Cheng; Zhi-Lian Wang; Qian-Yun Gu; Min Hao
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

5.  OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia.

Authors:  Rui Tong; Qing Yang; Chunyan Wang; Fangfang Bi; Bing Jiang
Journal:  Oncol Lett       Date:  2017-03-13       Impact factor: 2.967

6.  ≤ Cyclin D1 protein affecting global women's health by regulating HPV mediated adenocarcinoma of the uterine cervix.

Authors:  Richa Tripathi; Gayatri Rath; Poonam Jawanjal; Mausumi Bharadwaj; Ravi Mehrotra
Journal:  Sci Rep       Date:  2019-03-22       Impact factor: 4.379

7.  CyclinD1 Is a New Target Gene of Tumor Suppressor MiR-520e in Breast Cancer.

Authors:  Quan Liang; Qingjuan Yao; GuoYing Hu
Journal:  Open Med (Wars)       Date:  2019-12-04

8.  Research on the mechanisms of taraxerol for the treatment of gastric cancer effect based on network pharmacology.

Authors:  Bingjie Huo; Yanru Song; Bibo Tan; Jianbo Li; Jie Zhang; Fengbin Zhang; Liang Chang
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.